Disc Medicine (IRON) Other Accumulated Expenses (2020 - 2026)
Disc Medicine (IRON) posted quarterly Other Accumulated Expenses of $741000.0 for Q2 2026, down 8.52% year-over-year from $810000.0 in Q2 2025, and down 14.83% quarter-over-quarter from $870000.0 in Q1 2026.
Powered by 
Analysis
Disc Medicine (IRON) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Other Accumulated Expenses for 7 consecutive years, with $741000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Accumulated Expenses fell 8.52% year-over-year to $741000.0; the TTM figure through Jun 2026 stood at $741000.0 (down 8.52% YoY), while the FY2025 annual figure was $705000.0, up 98.59% from the prior year.
- Other Accumulated Expenses declined to $741000.0 in Q2 2026 per IRON's latest filing, from $870000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $870000.0 in Q1 2026 and bottomed at $52000.0 in Q4 2023.
- Historically, Other Accumulated Expenses has averaged $413800.0 across 5 years, with a median of $345000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 880.95% — and 2023, when it sank 74.76%.
- Disc Medicine's Other Accumulated Expenses stood at $206000.0 in 2022, then tumbled by 74.76% to $52000.0 in 2023, then soared by 582.69% to $355000.0 in 2024, then soared by 98.59% to $705000.0 in 2025, then climbed by 5.11% to $741000.0 in 2026.
- Business Quant data shows IRON's Other Accumulated Expenses at $741000.0 in Q2 2026, $870000.0 in Q1 2026, and $705000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 741,000.00 |
| Mar 31, 2026 | 870,000.00 |
| Dec 31, 2025 | 705,000.00 |
| Sep 30, 2025 | 749,000.00 |
| Jun 30, 2025 | 810,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 355,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | 199,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 189,000.00 |
| Mar 31, 2023 | 345,000.00 |
| Dec 31, 2022 | 206,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | 147,000.00 |
| Mar 31, 2021 | 87,000.00 |
| Dec 31, 2020 | 46,000.00 |